ERBB2 and breast neoplasm: Further, in mice that are immune-deficient, this plant-based anti-HER2 VHH-FcK antibody shows superior anticancer activity, particularly against Trastuzumab-resistant tumors, underscoring its potential as effective immunotherapy for HER2-positive breast tumors that are Trastuzumab-resistant.